drugset / Trial / NCT05859776
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question\[s\] it aims to answer are: * Safety of the maximum tolerable dose of AXT107 * Bioactivity and duration of action of AXT107 injected suprachoroidally Participants will be injected with AXT107 and will be followed on a regular monitoring visits through 9 months post single injection.
Timeline
- Start
- 2023-12-19
- Primary completion
- 2025-03
- Completion
- 2025-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GERSIZANGITIDE | Protein / enzyme biologic | 0.125 mg | Other |
| Subject | GERSIZANGITIDE | Protein / enzyme biologic | 0.25 mg | Other |
| Subject | GERSIZANGITIDE | Protein / enzyme biologic | 0.5 mg | Other |